Literature DB >> 17493472

Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion.

Maria Luisa Loricchio1, Cinzia Cianfrocca, Vincenzo Pasceri, Leopoldo Bianconi, Antonio Auriti, Leonardo Calo, Filippo Lamberti, Antonio Castro, Claudio Pandozi, Antonio Palamara, Massimo Santini.   

Abstract

The aim of this study is to assess the role of C-reactive protein (CRP) in predicting long-term risk of atrial fibrillation (AF) recurrence after electrical cardioversion. CRP levels are associated with the presence of AF and failure of electrical or pharmacologic cardioversion, but no previous study has assessed their predictive role in long-term follow-up after successful electrical cardioversion. One hundred two consecutive patients (age 67 +/- 11 years; 58 men) with nonvalvular persistent AF who underwent successful biphasic electrical cardioversion were studied. High-sensitivity CRP was measured immediately before cardioversion. Follow-up was performed up to 1 year in all cases. Patients were divided into 4 groups according to CRP quartiles. Patients in the lowest CRP quartile (<1.9 mg/L) had significantly lower rates of AF recurrence (4% vs 33% at 3 months in the other 3 groups combined, p = 0.007, and 28% vs 60% at 1 year, p = 0.01). The 4 groups were similar in age, gender, ejection fraction, and left atrial size. Survival analysis confirmed that patients in the lowest CRP quartile had a lower recurrence rate (p = 0.02). Cox regression analyses using age, gender, hypertension, diabetes, ejection fraction, left atrial diameter, use of antiarrhythmic drugs, angiotensin-converting enzyme inhibitors or angiotensin II antagonists, and statins, and CRP quartiles as covariates showed that only CRP was independently associated with AF recurrence during follow-up (hazard ratio 4.98, 95% confidence interval 1.75 to 14.26, p = 0.003). In conclusion, low CRP is associated with long-term maintenance of sinus rhythm after cardioversion for nonvalvular AF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17493472     DOI: 10.1016/j.amjcard.2006.12.074

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  17 in total

1.  A clinical prediction model to estimate risk for 30-day adverse events in emergency department patients with symptomatic atrial fibrillation.

Authors:  Tyler W Barrett; Amy R Martin; Alan B Storrow; Cathy A Jenkins; Frank E Harrell; Stephan Russ; Dan M Roden; Dawood Darbar
Journal:  Ann Emerg Med       Date:  2010-08-21       Impact factor: 5.721

Review 2.  Inflammation, a link between obesity and atrial fibrillation.

Authors:  Alina Scridon; Dan Dobreanu; Philippe Chevalier; Răzvan Constantin Şerban
Journal:  Inflamm Res       Date:  2015-05-01       Impact factor: 4.575

3.  C-Reactive Protein and The Risk of Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Authors:  Venkata M Alla; Senthil Thambidorai; Kishlay Anand; Aryan N Mooss; Richard Baltaro; Syed M Mohiuddin
Journal:  J Atr Fibrillation       Date:  2010-01-01

4.  Atrial fibrillation and inflammation.

Authors:  Mehmet Ozaydin
Journal:  World J Cardiol       Date:  2010-08-26

5.  Plasma YKL-40 is elevated in patients with recurrent atrial fibrillation after catheter ablation.

Authors:  Kristoffer Mads Henningsen; Brian Nilsson; Julia S Johansen; Xu Chen; Steen Pehrson; Jesper Hastrup Svendsen
Journal:  Inflamm Res       Date:  2009-12-10       Impact factor: 4.575

Review 6.  Pleiotropic effects of statins in atrial fibrillation patients: the evidence.

Authors:  Hadi Ar Hadi; Wael Al Mahmeed; Jassim Al Suwaidi; Samer Ellahham
Journal:  Vasc Health Risk Manag       Date:  2009-06-29

7.  High sensitivity C-reactive protein: a predictor for recurrence of atrial fibrillation after successful cardioversion.

Authors:  Enrico Vizzardi; Savina Nodari; Gregoriana Zanini; Alessandra Manerba; Silvia Frattini; Alberto Madureri; Riccardo Raddino; Livio Dei Cas
Journal:  Intern Emerg Med       Date:  2009-03-14       Impact factor: 3.397

Review 8.  The role of F18-fluorodeoxyglucose positron emission tomography in identifying patients at high risk for lethal arrhythmias from cardiac sarcoidosis and the use of serial scanning to guide therapy.

Authors:  Yehuda Edo Paz; Sabahat Bokhari
Journal:  Int J Cardiovasc Imaging       Date:  2013-11-30       Impact factor: 2.357

Review 9.  Non-antiarrhythmic medications for atrial fibrillation: from bench to clinical practice.

Authors:  Maya Guglin; Marcos Garcia; Michael J Yarnoz; Anne B Curtis
Journal:  J Interv Card Electrophysiol       Date:  2008-03-04       Impact factor: 1.900

10.  Plasma profiles of matrix metalloproteinases and tissue inhibitors of the metalloproteinases predict recurrence of atrial fibrillation following cardioversion.

Authors:  Rupak Mukherjee; Joseph G Akar; J Marcus Wharton; Deborah K Adams; Catherine D McClure; Robert E Stroud; Allison D Rice; Stacia M DeSantis; Francis G Spinale; Michael R Gold
Journal:  J Cardiovasc Transl Res       Date:  2013-05-31       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.